213 related articles for article (PubMed ID: 22322364)
1. Combination of Temsirolimus and tyrosine kinase inhibitors in renal carcinoma and endothelial cell lines.
Martin B; Edeline J; Patard JJ; Oger E; Jouan F; Boulanger G; Zerrouki S; Vigneau C; Rioux-Leclercq N
J Cancer Res Clin Oncol; 2012 Jun; 138(6):907-16. PubMed ID: 22322364
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of endothelial cell phosphoinositide 3-kinase β inhibits tumor angiogenesis and tumor growth.
Azad AK; Zhabyeyev P; Vanhaesebroeck B; Eitzen G; Oudit GY; Moore RB; Murray AG
Oncogene; 2020 Oct; 39(41):6480-6492. PubMed ID: 32879446
[TBL] [Abstract][Full Text] [Related]
3. Systemic therapy for metastatic non-clear-cell renal cell carcinoma: recent progress and future directions.
Chowdhury S; Matrana MR; Tsang C; Atkinson B; Choueiri TK; Tannir NM
Hematol Oncol Clin North Am; 2011 Aug; 25(4):853-69. PubMed ID: 21763971
[TBL] [Abstract][Full Text] [Related]
4. The relevance of testing the efficacy of anti-angiogenesis treatments on cells derived from primary tumors: a new method for the personalized treatment of renal cell carcinoma.
Grépin R; Ambrosetti D; Marsaud A; Gastaud L; Amiel J; Pedeutour F; Pagès G
PLoS One; 2014; 9(3):e89449. PubMed ID: 24676409
[TBL] [Abstract][Full Text] [Related]
5. A "game of thrones" in metastatic renal cell carcinoma: vascular endothelial growth factor-tyrosine kinase inhibitors and mammalian target of rapamycin inhibitors battling for position.
Pal SK; Vogelzang NJ
Clin Genitourin Cancer; 2013 Mar; 11(1):1-4. PubMed ID: 23276588
[No Abstract] [Full Text] [Related]
6. Angiostatic kinase inhibitors to sustain photodynamic angio-occlusion.
Nowak-Sliwinska P; Weiss A; van Beijnum JR; Wong TJ; Ballini JP; Lovisa B; van den Bergh H; Griffioen AW
J Cell Mol Med; 2012 Jul; 16(7):1553-62. PubMed ID: 21880113
[TBL] [Abstract][Full Text] [Related]
7. Beyond traditional outcomes: improving quality of life in patients with renal cell carcinoma.
Cella D
Oncologist; 2011; 16 Suppl 2(Suppl 2):23-31. PubMed ID: 21346037
[TBL] [Abstract][Full Text] [Related]
8. Effects of preset sequential administrations of sunitinib and everolimus on tumour differentiation in Caki-1 renal cell carcinoma.
Dos Santos C; Tijeras-Raballand A; Serova M; Sebbagh S; Slimane K; Faivre S; de Gramont A; Raymond E
Br J Cancer; 2015 Jan; 112(1):86-94. PubMed ID: 25422908
[TBL] [Abstract][Full Text] [Related]
9. Two drug interaction studies of sirolimus in combination with sorafenib or sunitinib in patients with advanced malignancies.
Gangadhar TC; Cohen EE; Wu K; Janisch L; Geary D; Kocherginsky M; House LK; Ramirez J; Undevia SD; Maitland ML; Fleming GF; Ratain MJ
Clin Cancer Res; 2011 Apr; 17(7):1956-63. PubMed ID: 21447721
[TBL] [Abstract][Full Text] [Related]
10. High dose intermittent sorafenib shows improved efficacy over conventional continuous dose in renal cell carcinoma.
Wang X; Zhang L; Goldberg SN; Bhasin M; Brown V; Alsop DC; Signoretti S; Mier JW; Atkins MB; Bhatt RS
J Transl Med; 2011 Dec; 9():220. PubMed ID: 22188900
[TBL] [Abstract][Full Text] [Related]
11. Analyses of potential predictive markers and survival data for a response to sunitinib in patients with metastatic renal cell carcinoma.
Dornbusch J; Zacharis A; Meinhardt M; Erdmann K; Wolff I; Froehner M; Wirth MP; Zastrow S; Fuessel S
PLoS One; 2013; 8(9):e76386. PubMed ID: 24086736
[TBL] [Abstract][Full Text] [Related]
12. A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs.
Pauty J; Usuba R; Cheng IG; Hespel L; Takahashi H; Kato K; Kobayashi M; Nakajima H; Lee E; Yger F; Soncin F; Matsunaga YT
EBioMedicine; 2018 Jan; 27():225-236. PubMed ID: 29289530
[TBL] [Abstract][Full Text] [Related]
13. Antiangiogenic therapy for breast cancer.
Nielsen DL; Andersson M; Andersen JL; Kamby C
Breast Cancer Res; 2010; 12(5):209. PubMed ID: 21067536
[TBL] [Abstract][Full Text] [Related]
14. Enhanced synergy of pacritinib with temsirolimus and sunitinib in preclinical renal cell carcinoma model by targeting JAK2/STAT pathway.
Mao F; Gao L; Liu L; Tang Y
J Chemother; 2024 May; 36(3):238-248. PubMed ID: 37916436
[TBL] [Abstract][Full Text] [Related]
15. Phase I study combining treatment with temsirolimus and sunitinib malate in patients with advanced renal cell carcinoma.
Patel PH; Senico PL; Curiel RE; Motzer RJ
Clin Genitourin Cancer; 2009 Jan; 7(1):24-7. PubMed ID: 19213664
[TBL] [Abstract][Full Text] [Related]
16. Cox-2 inhibition enhances the activity of sunitinib in human renal cell carcinoma xenografts.
Wang X; Zhang L; O'Neill A; Bahamon B; Alsop DC; Mier JW; Goldberg SN; Signoretti S; Atkins MB; Wood CG; Bhatt RS
Br J Cancer; 2013 Feb; 108(2):319-26. PubMed ID: 23322198
[TBL] [Abstract][Full Text] [Related]
17. A serum metabolomic fingerprint of bevacizumab and temsirolimus combination as first-line treatment of metastatic renal cell carcinoma.
Jobard E; Blanc E; Négrier S; Escudier B; Gravis G; Chevreau C; Elena-Herrmann B; Trédan O
Br J Cancer; 2015 Oct; 113(8):1148-57. PubMed ID: 26372698
[TBL] [Abstract][Full Text] [Related]
18. Low-dose taxotere enhances the ability of sorafenib to induce apoptosis in gastric cancer models.
Tesei A; Leonetti C; Zupi G; Scarsella M; Brigliadori G; Ulivi P; Fabbri F; Arienti C; Amadori D; Passardi A; Silvestrini R; Zoli W
J Cell Mol Med; 2011 Feb; 15(2):316-26. PubMed ID: 20015197
[TBL] [Abstract][Full Text] [Related]
19. The induction of human myeloid derived suppressor cells through hepatic stellate cells is dose-dependently inhibited by the tyrosine kinase inhibitors nilotinib, dasatinib and sorafenib, but not sunitinib.
Heine A; Schilling J; Grünwald B; Krüger A; Gevensleben H; Held SA; Garbi N; Kurts C; Brossart P; Knolle P; Diehl L; Höchst B
Cancer Immunol Immunother; 2016 Mar; 65(3):273-82. PubMed ID: 26786874
[TBL] [Abstract][Full Text] [Related]
20. Intra-tumour molecular heterogeneity of clear cell renal cell carcinoma reveals the diversity of the response to targeted therapies using patient-derived xenograft models.
Hong B; Yang Y; Guo S; Duoerkun S; Deng X; Chen D; Yu S; Qian W; Li Q; Li Q; Gong K; Zhang N
Oncotarget; 2017 Jul; 8(30):49839-49850. PubMed ID: 28548943
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
